APA (7th ed.) Citation

He, Y., Sadler, B. M., Sabo, R., Balez, S., Wang, Y., Campestrini, J., . . . Howard, D. (2007). The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers. Clinical pharmacokinetics, 46(9), 787-802. https://doi.org/10.2165/00003088-200746090-00006

Chicago Style (17th ed.) Citation

He, Yan-Ling, Brian M. Sadler, Ron Sabo, Sebastien Balez, Yibin Wang, Joelle Campestrini, Aziz Laurent, Monica Ligueros-Saylan, and Dan Howard. "The Absolute Oral Bioavailability And??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers." Clinical Pharmacokinetics 46, no. 9 (2007): 787-802. https://doi.org/10.2165/00003088-200746090-00006.

MLA (9th ed.) Citation

He, Yan-Ling, et al. "The Absolute Oral Bioavailability And??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers." Clinical Pharmacokinetics, vol. 46, no. 9, 2007, pp. 787-802, https://doi.org/10.2165/00003088-200746090-00006.